TRAQinform IQ
by AIQ Solutions
· Based in United States →
— Improving treatment outcomes for patients with a wide range of complex diseases.
Regulatory Status Disclosed
Overview
TRAQinform IQ by AIQ Solutions (AIQ Global) is an FDA-cleared software medical device designed to provide automated, lesion-level quantitative analysis of treatment response in patients with complex, late-stage, or metastatic cancers.
The software is built for trained medical professionals, including:
- Oncologists
- Nuclear medicine physicians and radiologists
- Medical imaging technologists, dosimetrists, and physicists
Operating in clinical oncology and radiology workflows, TRAQinform IQ utilizes serial radiographic images, such as PET and CT DICOM 3.0 volumetric scans. Images are uploaded securely to the cloud, where the software automatically segments anatomical structures and matches regions of interest (ROIs) across longitudinal scans. This process tracks the behavior of individual lesions over time to evaluate intra-patient treatment heterogeneity.
Notable capabilities of the platform include:
- Automated matching of ROIs between baseline and follow-up PET/CT and CT imaging.
- Generation of visual and quantitative reports detailing the rate of change (slope) and spatial location of resistant disease for each tracked lesion.
- Color-coded visual mapping to assist clinicians in distinguishing between responding and progressing lesions.
- Support for monitoring multiple cancer types, including lung, prostate, bladder, head and neck, neuroendocrine, melanoma, and lymphoma.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Clinical decision support
- Patient monitoring
- Data analytics
- Interoperability
- Medical imaging
- Automated anatomical and skeletal segmentation
- Automated matching and quantitative assessment of ROIs between multiple PET/CT scans
- Generates detailed reports on lesion volume and tracer uptake changes
- Lesion-level analysis for treatment response heterogeneity
- Real-time analysis and reporting
Use Cases
- Monitoring disease progression in oncology
- Monitoring treatment response in oncology and nuclear medicine
- Adjusting therapies and optimizing clinical outcomes
- Understanding treatment response heterogeneity in cancer patients
- Guiding timely and effective treatment decisions for advanced cancer patients
- Supporting early-stage clinical trials for drug effect and toxicity analysis
What Physicians Need to Know
Key Capabilities
TRAQinform IQ is a software medical device that quantifies changes in cancer lesions over time using serial radiographic images (PET, CT). It provides novel quantitative and spatial information about changes in regions of interest (ROI) to help oncologists adjust therapies and optimize clinical outcomes. The technology performs longitudinal matching of ROIs between images of patients with advanced metastatic cancers. It displays changes to all areas with cancer using 3D images, guiding oncologists to effective treatments. The software identifies changes in each area of metastatic cancer, providing a detailed report to pinpoint which cancers are responding to treatment. It also measures intra-patient heterogeneity through metrics like SUVhetero.
Clinical Utility
TRAQinform IQ provides clinicians with lesion-level analysis, offering clearer insights into patterns of treatment response heterogeneity than traditional imaging assessments. This precision can influence treatment decisions and improve potential outcomes for patients with advanced cancer. It helps oncologists make treatment decisions based on the collective behavior of every lesion, enabling personalized medicine. The technology is used to support clinical decisions around the use of theranostics and for theranostics treatment optimization. It has been incorporated into the care of patients with prostate, bladder, melanoma, lymphoma, lung, head and neck, and neuroendocrine cancers in several hospitals.
Integration Options
TRAQinform IQ integrates into existing clinical workflows. Images are uploaded via a HIPAA-compliant cloud to AIQ Solutions, and a comprehensive report is generated and delivered to the oncologist. The software uses serial radiographic images (e.g., PET, CT).
Compliance Status
TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444 and K233998. The American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code (X567T) for the technology, recognizing its unique analysis for tracking lesion changes in cancer patients over time. This CPT code is for tracking and is not eligible for reimbursement, but it represents positive momentum for AI use in healthcare.
Pricing Model
Not specified in the provided context.
User Experience
TRAQinform IQ presents a visual report where responding lesions appear in green and progressing lesions in red. It also provides a written report detailing the rate of change of each lesion and any change in the spatial location of resistant disease. The process of automated matching significantly expedites analysis, taking an average of 4 minutes in high-burden cases compared to 30-60 minutes for physicians.
Support Quality
AIQ Solutions ensures high standards of quality and integrity across its end-to-end clinical workflow, from imaging data entry to report delivery. The development process involves translating customer needs into product features, coordinating resources, managing timelines, and rigorous verification and validation testing. All aspects of the analysis process are monitored by an experienced imaging expert to ensure algorithms work as expected, and by a nuclear medicine physician to ensure lesion-ROIs are correctly detected and classified.
Implementation Complexity
The software is designed for easy integration into existing workflows. Images can be sent electronically from hospitals or imaging centers to AIQ Solutions.
Evidence Base
The technology is supported by publications and clinical research. A retrospective study comparing TRAQinform IQ technology with expert nuclear medicine physicians demonstrated high performance for matching ROI, on-par with the variability between physicians. In a retrospective study of patients with metastatic lung cancer and lymphoma, analysis by TRAQinform IQ was more prognostic of overall survival than standard-of-care methods (RECIST, PERCIST, global SUVpeak, and global volume). A Pfizer study published in 2020 established the foundational science, showing that not every lesion responds similarly to treatment and drug resistance in a small percentage of lesions can drive poor overall clinical outcomes. The software has been validated for accurate anatomic structure segmentation, lesion-ROI detection, and matching ROI across time.
Physician Tip
TRAQinform IQ offers a detailed, lesion-level view of treatment response in metastatic cancer, which can be crucial for tailoring therapies. The visual reports (green for responding, red for progressing lesions) and quantitative data on lesion change rates provide a comprehensive understanding beyond traditional binary assessments. This tool can help identify resistant lesions early, allowing for more timely adjustments to treatment plans and potentially improving patient outcomes. Consider integrating this into your workflow for patients with complex metastatic disease, especially when heterogeneity of response is suspected. The AMA's approval of a Category III CPT code indicates growing recognition, though direct reimbursement is not yet available.
TRAQinform IQ is designed for easy integration into existing clinical workflows, primarily by accepting serial radiographic images (PET, CT) uploaded via a HIPAA-compliant cloud. The analysis is performed by AIQ Solutions, and a detailed report is then delivered back to the oncologist. This cloud-based approach simplifies the technical integration for healthcare providers.
Details
| Category | Oncology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | Cloud-based |
| Data Export | Yes |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| SOC 2 | Yes AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Nuclear Medicine, Oncology, Radiology |
What the Web Says
TRAQinform IQ, developed by AIQ Solutions, is a software medical device that provides quantitative assessment of treatment response heterogeneity in late-stage cancer patients. It analyzes serial radiographic images (PET, CT) to measure changes in lesion regions of interest over time, offering oncologists novel quantitative and spatial information to optimize therapy selection and clinical outcomes. The technology has received FDA clearance and a new Category III CPT code, indicating its recognition in the medical field. Physicians have found the analysis useful for systemic therapy decisions, targeted therapy decisions, spatial location information, and patient education.
Overall: PositiveStrengths
- Provides novel quantitative and spatial information for oncologists to optimize therapy selection and clinical outcomes.
- More prognostic of overall survival than standard-of-care methods in retrospective studies of metastatic lung cancer and lymphoma.
- Integrates into existing clinical workflows via HIPAA-compliant cloud-based image upload and automated report generation.
- FDA-cleared software medical device.
- Received a new Category III CPT code for lesion heterogeneity assessment.
- Oncologists found the analysis useful for systemic therapy decisions, targeted therapy decisions, spatial location information, and patient education.
Limitations
No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.
Based on reviews from: G2.com, ResearchGate, FDA.gov, Indeed.com, MedIndexer, AIQ Solutions, ASCO.org, NIH.gov, Radiology Business, Cancer Network, Capterra, Reddit, Trustpilot
Last updated: 2026-10-28
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate TRAQinform IQ
Press & Coverage
PR Newswire
AIQ Solutions Announces a New Category III CPT Code for Determining Heterogeneity of Change Across All Lesions for Advanced Metastatic Cancer Used with TRAQinform IQ Technology
AIQ Solutions announced that the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code for its TRAQinform IQ technology, a significant step towards broader clinical adoption and accessibility of advanced treatment response intelligence for oncologists and patients. This code recognizes the unique lesion-level analysis provided by TRAQinform IQ, offering clearer insights into treatment response heterogeneity than traditional imaging assessments.
2026-03
HHM Global
AIQ Solutions Receives AMA Category III CPT Code for TRAQinform IQ Technology, Enabling Lesion-Level Treatment Response Insights for Advanced Cancer
AIQ Solutions has received a Category III CPT code from the AMA for its TRAQinform IQ technology, following years of clinical validation, regulatory engagement, and operational preparation. This code facilitates lesion-level analysis, providing oncologists with detailed insights into treatment response heterogeneity in advanced cancer patients.
2026-03
aiq-solutions.com
AIQ Solutions Announces New Category III CPT Code for TRAQinform IQ Technology
AIQ Solutions announced the approval of a new Category III CPT code by the AMA for its TRAQinform IQ technology, which provides unique insights into treatment response by quantifying changes in regions of interest over time. This milestone aims to make advanced treatment response intelligence more accessible to oncologists and patients.
2026-04
Radiology Business
New CPT code issued for AI-enabled lesion tracking in cancer patients
The American Medical Association has approved a new Category III CPT code for AIQ Solutions' TRAQinform IQ technology, which tracks lesion changes in cancer patients over time. This software, first cleared by the FDA in 2018, offers clinicians detailed insights into treatment response, potentially allowing for earlier adjustments to care plans.
2026-03
CancerX
AIQ Solutions Honored with Discovery Acceleration Award at CancerX 2025 Accelerator
AIQ Solutions received the inaugural Discovery Acceleration Award at the CancerX 2025 Accelerator graduation ceremony for its TRAQinform IQ technology, recognized for its potential to accelerate clinical trials and improve patient access to treatments. The technology brings precision to metastatic cancer monitoring by addressing the varied responses of individual lesions to treatment.
2025-07
Journal of Nuclear Medicine
Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study
A study published in the Journal of Nuclear Medicine explored the prognostic value of AI-assisted lesion tracking using TRAQinform IQ technology in metastatic castration-resistant prostate cancer (mCRPC) patients. The technology provides in-depth quantitative analysis of lesion-by-lesion changes from PSMA PET scans to assess treatment response and predict overall survival.
2025-09
The Imaging Wire
AIQ Solutions and Blackford Analysis Partner to Integrate TRAQinform IQ into Blackford Platform
Blackford Analysis has partnered with AIQ Solutions to integrate AIQ's TRAQinform IQ tool into the Blackford platform, providing users with access to AIQ's clinical decision support technology for analyzing and quantifying metastatic tumors. This collaboration expands the capabilities of the Blackford platform with advanced AI-powered imaging analysis.
2023-11
NIH.gov (originally from European Journal of Nuclear Medicine and Molecular Imaging)
AI-assisted immunotherapy response analysis using 18F-FDG PET-CT in metastatic melanoma
A study published in the European Journal of Nuclear Medicine and Molecular Imaging utilized TRAQinform IQ software to analyze FDG PET/CT images for automated quantification and analysis of early anatomical and functional changes in metastatic non-small cell lung cancer and diffuse large B-cell lymphoma patients. The software performs quantitative analysis of heterogeneity of change in volume and tracer-uptake using automated matching of lesion-ROIs.
2024-05
Videos
Product demos, reviews, and walkthroughs for TRAQinform IQ.
Eric Horler: New Technology Transforming Oncology Decision-Making
Root3 Marketing
Frequently Asked Questions
TRAQinform IQ is a software medical device that provides quantitative and spatial information about changes in regions of interest over time, based on analysis of serial radiographic images (e.g., PET, CT). This technology helps oncologists more precisely adjust therapies and optimize clinical outcomes by providing a detailed map of how each area in a patient's body is responding to treatment.
Yes, TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444 and K233998. Images are uploaded via the cloud to AIQ Solutions in a HIPAA-compliant manner.
In retrospective studies, TRAQinform IQ technology has been shown to be more prognostic of overall survival than standard-of-care methods, including RECIST, PERCIST, global SUVpeak, and global volume, in patients with metastatic lung cancer and lymphoma. It provides a more comprehensive picture of a metastatic cancer patient's disease by analyzing individual lesion responses, which can lead to more informed decision-making.
While TRAQinform IQ provides advanced automated analysis, its limitations include potential changes in non-target lesions. It's important to remember that AI tools like TRAQinform IQ are designed to support, not replace, clinical judgment.
The American Medical Association has approved a new Category 3 Current Procedural Terminology (CPT) code (X567T) for TRAQinform IQ technology. However, Category 3 codes are primarily for tracking new technologies and are not yet eligible for reimbursement.
Compare TRAQinform IQ
VS
TRAQinform IQ vs Viz CTP
TRAQinform IQ specializes in quantitative analysis of lesions in PET/CT scans for oncology and nuclear medicine, focusing on monitoring disease progression and treatment response. In contrast, Viz CTP…
VS
TRAQinform IQ vs VIDAvision
TRAQinform IQ specializes in quantitative analysis of lesions in PET/CT scans for oncology and nuclear medicine, focusing on disease progression and treatment response. In contrast, VIDAvision provides comprehensive…
VS
TRAQinform IQ vs QuantX
TRAQinform IQ is designed for quantitative analysis of lesions in PET/CT scans to monitor disease progression and treatment response in oncology. In contrast, QuantX focuses on computer-aided diagnosis…
VS
TRAQinform IQ vs Constellation (CON-001)
Tool A is designed for quantitative analysis of lesions in PET/CT scans, aiding clinicians in monitoring disease progression and treatment response in oncology and nuclear medicine. Tool B,…
Suggest an Edit → | Report an issue
| Last Verified: 2026-10-14 | First Added: 2026-04-17